Abstracts Archive - Page 1490 of 1683 - ATC Abstracts

2015 American Transplant Congress
Conversion from Immediate to Prolonged Release Tacrolimus Did Not Change Intra-Patient Variability in Renal Transplant Patients
T. El-Nahhas,^1,2 M. Moreton,² J. Popoola,³ S. Abat,³ A. Johnston,^1,2 I. MacPhee.³
¹Clinical Pharmacology Department, William Harvey Research Institute, Barts and The London, Queen Mary University of London, London, United Kingdom; ²Analytical Services International, St. George's University of London, London, United Kingdom; ³Institute of Medical and Biomedical Education-Renal Medicine, St. George's University of London, London, United Kingdom.
Background. Tacrolimus has a narrow therapeutic index and is characterized by a large inter- and intra-patient variability (IPV). Variable blood tacrolimus concentrations have been shown…
2015 American Transplant Congress
Prospective Study of a Steroid Free, Low Dose Tacrolimus and Everolimus Combination Regimen in Kidney Transplant
A. Shetty,¹ J. Leventhal,¹ O. Traitanon,¹ A. Alvarado,¹ V. Mas,² J. Mathew,¹ E. Tantisattamo,¹ L. Gallon.¹
¹Nephrology/Comprehensive Transplant, Northwestern University, Chicago; ²Surgery, Virginia Commonwealth University, Richmond.
Calcineurin(CNI) based therapy is the cornerstone of immunosuppresion(IS) after kidney transplant. However chronic nephrotoxicity from CNI as been implicated in post-transplant renal dysfunction. We hypothesized…
2015 American Transplant Congress
2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients
T. Yagisawa,¹ N. Ishikawa,¹ N. Goto,² I. Nakajima,³ O. Kamisawa,⁴ S. Fuchinoue.³
¹Division of Renal and Transplantation, Jichi Medical University, Shimotsuke, Japan; ²Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ³Surgery, Kidney Center, Tokyo Women's University, Tokyo, Japan; ⁴Medical Division, Novartis Pharma K.K., Tokyo, Japan.
Purpose: The long-term effects of everolimus (EVR) with reduced cyclosporine (rCsA) exposure over 24 months on renal function and safety (viral infection) were assessed in…
2015 American Transplant Congress
Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine Versus Tacrolimus Based Immunosuppression Regimen
P. West-Thielke,¹ M. Campara,² A. Ladik,¹ E. Terranova,² E. Benedetti,¹ J. Thielke.²
¹Surgery, University of Illinois, Chicago; ²Pharmacy Practice, University of Illinois, Chicago.
Purpose: In 2005, an internal retrospective study at our institution showed a higher incidence of post transplant diabetes mellitus (PTDM) in our Hispanic kidney transplant…
2015 American Transplant Congress
Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?
R. Ciria Bru, I. Gómez Luque, M. Cortés Cerisuelo, P. López Cillero, J. O'Grady, M. de la Mata, N. Heaton, J. Briceño Delgado.
Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatology and Liver Transplantation, University Hospital Reina Sofía, Córdoba, Spain; Institute of Liver Studies, King's College Hospital, London, United Kingdom; Unit of Hepatobiliary Surgery and Liver Transplantation, University Reina Sofia Hospital, Córdoba, Spain.
Acute kidney injury(AKI)after liver transplantation (LT) is common.Calcineurin inhibitors(CNI)have to be well-balanced.The aims were analyze the specific effect of CNI on AKI in a cohort…
2015 American Transplant Congress
Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant
M. Mariski,¹ A. DeGolovine,² W. Dar,² J. Bynon,² H. Adrogué,² M. Hobeika.²
¹Dept of Pharmacy, Memorial Hermann Texas Medical Center, Houston, TX; ²Division of Immunology and Organ Transplantation, University of Texas, Houston, TX.
Purpose: To evaluate the effects of a reduced intensity immunosuppression protocol on drug costs and rates of BK viremia and readmissions.Methods: In response to high…
2015 American Transplant Congress
Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)
M. Molina,¹ E. Gutierrez,¹ S. González-Sanchidrian,² E. González,¹ J. Cabrera,¹ N. Polanco,¹ A. Hernández,¹ A. Sevillano,¹ M. Praga,¹ A. Andres.¹
¹Nephrology, Hospital 12 de Octubre, Madrid, Spain; ²Nephrology, Hospital San Pedro de Alcántara, Caceres, Spain.
INTRODUCTION: Ischemia injury in kidneys grafts from UDCDD could produce a poor renal function. Minimized blood levels of CNI associated with i-mTOR therapy could avoid…
2015 American Transplant Congress
Delayed Tacrolimus (TAC) to Rapamycin (RAPA) Conversion in Renal Transplant Recipients With DGF/SGF
A. Haririan,¹ D. Klassen,¹ M. Keshtkar,¹ C. Drachenberg,² T. Dowling,³ E. Ramos,¹ R. Ugarte,¹ C. Cangro,¹ M. Weir.¹
¹Medicine, University of Maryland, Baltimore, MD; ²Pathology, University of Maryland, Baltimore, MD; ³Pharmacy, University of Maryland, Baltimore, MD.
The role of conversion from TAC to RAPA early after kidney transplantation in patients with DGF/SGF in improving graft function and delaying chronic allograft dysfunction…
2015 American Transplant Congress
mTOR-Based CNI Minimization Vs Withdrawal in African American Kidney Transplant Recipients
J. Fleming,¹ D. Taber,² N. Pilch,¹ H. Meadows,¹ C. Mardis,¹ J. McGillicuddy,² S. Nadig,² K. Chavin,² P. Baliga,² C. Bratton.²
¹Pharmacy, Medical University of South Carolina, Charleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC.
The purpose of this study was to compare mTOR-based CNI withdrawal vs. minimization in African American (AA) kidney transplant (KTx) recipients.METHODS: This was a single-center,…
2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
W. Arns,¹ K. Budde,¹ C. Sommerer,¹ O. Witzke,¹ M. Guba,¹ J. Jacobi,¹ B. Vogt,³ P. Reinke,¹ I. Hauser,¹ R. Stahl,¹ T. Rath,¹ D. Baeumer,² M. Porstner,² M. Zeier,¹ F. Lehner,¹ V. Kliem.¹
¹Herakles Study Group, Germany; ²Novartis, Pharma, Germany; ³Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…